Myfortic Tablets, 180 and 360 mg

NOVARTIS PHARMACEUTICALS CORPORATION

Revision date : 2004-03-10

SDS Library

Move your SDS library online today

Check Icon
Setup – Easy setup with our database of 16 million+ SDSs
Check Icon
Up-to-date – Your SDS get updated to latest versions.
Check Icon
Employee access – Tablets, Smartphones, or link from Corporate Intranet
Check Icon
Safety – One-click access to first aid information.
Check Icon
Labels – Generate Secondary Container Labels with just one click.
Health risk rating 1
Safety risk rating 1
Environmental risk rating 1

General Information

Revision date

2004-03-10

Product name

Myfortic Tablets, 180 and 360 mg

Product Synonyms

Mycophenolic Acid Tablets

Chemical name

(E)-6-(4-hydroxy-6-methoxy-7-methyl-3-oxo-1,3-dihydroisobenzofuran-5-yl)-4- methylhex-4-enoic acid salt

CAS No.

24280-93-1

Icons in SDS

Company Information

company name

NOVARTIS PHARMACEUTICALS CORPORATION

Section 2

SECTION 2: Hazards identification

EMERGENCY OVERVIEW *************************************************************************************************** FINISHED PHARMACEUTICAL PRODUCT REFER TO PHYSICIANS' DESK REFERENCE OR PACKAGE INSERT IMMUNOSUPPRESANT AGENT MAY CAUSE GASTROINTESTINAL DISORDERS MAY CAUSE INCREASED SUSCEPTIBILITY TO INFECTION MAY ADVERSELY AFFECT THE DEVELOPING FETUS ***************************************************************************************************

Principle Routes of Exposure

Oral EFFECTS OF OVEREXPOSURE: Finished pharmaceutical product. Potential for exposure is reduced in this form. Skin: No hazard is expected from normal clinical use. Eye: No hazard is expected from normal clinical use. Inhalation: No hazard is expected from normal clinical use. Ingestion: No hazard is expected from normal clinical use. THERAPEUTIC SIDE EFFECTS: Anemia, leucopenia, constipation, nausea, diarrhea, vomiting, urinary tract infection, and insomnia. TARGET ORGAN EFFECTS: Affects the blood and blood-forming organs. REPRODUCTIVE HAZARDS: Pregnancy Category C. Experimental reproductive effects have been reported. (see section 11). CARCINOGENICITY: Not carcinogenic. (see section 11). MUTAGENICITY: Positive in two in vitro assays and one in vivo assay; negative in two other in vitro assays. (see Section 11).

Medical Conditions Generally Aggravated by Exposure

Known hypersensitivity to Myfortic or any of its excipients

SDS Library

Move your SDS library online today

Check Icon
Setup – Easy setup with our database of 16 million+ SDSs
Check Icon
Up-to-date – Your SDS get updated to latest versions.
Check Icon
Employee access – Tablets, Smartphones, or link from Corporate Intranet
Check Icon
Safety – One-click access to first aid information.
Check Icon
Labels – Generate Secondary Container Labels with just one click.